C4059023_interactsWith_C4045305 | Knowledge4COVID-19

Property	Value
?:effect	<https://research.tib.eu/covid-19/entity/C0001688>
?:hasPrimarySource	<https://research.tib.eu/covid-19/SourceName/UMLS>
?:impact	increase
?:interaction	The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Anetumab ravtansine.
?:objectDrug	<https://research.tib.eu/covid-19/entity/C4045305>
?:object_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB14809>
?:precipitantDrug	<https://research.tib.eu/covid-19/entity/C4059023>
?:precipitant_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB09057>
is ?:subClassOf of	<https://research.tib.eu/covid-19/entity/C4059023_hasPharmacodynamic_C4045305>
?:type	<https://research.tib.eu/covid-19/vocab/DrugDrugInteraction>

Metadata

Anon_0

<http://purl.org/net/provenance/ns#createdBy>

Anon_1

expand all